Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine for prevention of drug-induced hepatitis in acute lymphoblastic leukemia
IRCT20190202042583N4Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levocarnitine in acute lymphoblastic leukemia (ALL) and hepatitis, sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Incidence of drug-induced hepatitis. Started Mar 2023; status: completed.
02
Drugs
levocarnitine
03
Conditions
acute lymphoblastic leukemia (ALL)hepatitis
Beyond the preview
Go deeper on IRCT20190202042583N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190202042583N4.